Targeting the PI3K Pathway in HR+/HER2- MBC

Download this slideset to review the latest clinical data on the evolving role of mTOR, PIK3, and ALK inhibitors in the treatment of HR+/HER2- metastatic breast cancer.
Sara Hurvitz, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.05 MB
Released: May 31, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: September 23, 2020

Read this commentary from Clinical Care Options to gain expert perspectives on PARP inhibition in early, metastatic, and triple-negative breast cancer.

Mark E. Robson, MD Released: September 22, 2020

On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Expert commentary from Cristina Saura, MD, PhD, with answers to frequently asked questions on managing HER2-positive metastatic breast cancer from CCO

person default Cristina Saura, MD, PhD Released: September 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue